Screener
PTC Therapeutics PTCT US — PP&E (Net)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: PTC Therapeutics’s 10-K, filed February 19, 2026.
- Filed
- Feb 19, 2026, 4:36 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-017575
| Line item | United States | Non-US | Total |
|---|---|---|---|
| Total assets | $2,525,035 | $373,732 | $2,898,767 |
| Fixed assets, net | $54,109 | $1,262 | $55,371 |
| Revenue | $1,494,767 | $235,888 | $1,730,655 |
| Year Ended December 31, 2024 | |||
| United States | Non-US | Total | |
| Total assets | $1,343,234 | $361,790 | $1,705,024 |
| Fixed assets, net | $59,748 | $1,222 | $60,970 |
| Revenue | $413,044 | $393,736 | $806,780 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is PTC Therapeutics's US — PP&E (net)?
- PTC Therapeutics (PTCT) reported US — PP&E (net) of $54.11M in Q4 2025.
- How has PTC Therapeutics's US — PP&E (net) changed year-over-year?
- PTC Therapeutics's US — PP&E (net) decreased by 9.4% year-over-year, from $59.75M to $54.11M.
- What does US — PP&E (net) mean?
- This metric measures the net book value of the company's physical infrastructure, such as laboratories, manufacturing facilities, and office equipment, situated in the United States. It reflects the company's investment in the physical capacity required to support its research, development, and commercialization activities. Changes in this metric indicate the company's commitment to expanding or maintaining its domestic operational footprint.
Ask your AI about PTC Therapeutics's us — pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude